Cytokinetics disclosed full pivotal trial results for aficamten in non-obstructive hypertrophic cardiomyopathy (nHCM), showing improvements in how patients felt and in exercise capacity. The company said it is preparing a U.S. FDA submission by year-end, aiming to secure the first treatment specifically cleared for this patient population. The data, released as Cytokinetics unveiled the complete study record, come as cardiology competitors continue to refine targeted approaches for hypertrophic cardiomyopathy and downstream symptoms. Clinical experts said benefits may be modest, but the company’s planned timeline indicates an intent to move quickly if regulators accept the evidence package.